Global Molecular Diagnostics Partnering Terms and Agreements 2014 - 2020 -

DUBLIN--()--The "Global Molecular Diagnostics Partnering Terms and Agreements 2014 to 2020" report has been added to's offering.

The Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.

The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 7650 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Key Benefits:

  • In-depth understanding of Molecular Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Molecular Diagnostics dealmakers since 2014
  • Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Molecular Diagnostics dealmaking

2.1. Introduction

2.2. Molecular Diagnostics partnering over the years

2.3. Most active Molecular Diagnostics dealmakers

2.4. Molecular Diagnostics partnering by deal type

2.5. Molecular Diagnostics partnering by therapy area

2.6. Deal terms for Molecular Diagnostics partnering

2.6.1 Molecular Diagnostics partnering headline values

2.6.2 Molecular Diagnostics deal upfront payments

2.6.3 Molecular Diagnostics deal milestone payments

2.6.4 Molecular Diagnostics royalty rates

Chapter 3 - Leading Molecular Diagnostics deals

3.1. Introduction

3.2. Top Molecular Diagnostics deals by value

Chapter 4 - Most active Molecular Diagnostics dealmakers

4.1. Introduction

4.2. Most active Molecular Diagnostics dealmakers

4.3. Most active Molecular Diagnostics partnering company profiles

Chapter 5 - Molecular Diagnostics contracts dealmaking directory

5.1. Introduction

5.2. Molecular Diagnostics contracts dealmaking directory

Chapter 6 - Molecular Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Companies Mentioned

  • 2bPrecise
  • 3PrimeDx
  • 10X Genomics
  • 14M Genomics
  • A*STAR Agency for Science
  • Technology and Research
  • AB Analitica
  • Abbott Laboratories
  • Abbvie
  • Abcam
  • Abcodia
  • Abramson Cancer Center
  • AccuGenomics
  • AccuRef Diagnostics
  • AC Immune
  • Acumen Pharmaceuticals
  • Adaptive Biotechnologies
  • ADMA Biologics
  • Admera Health
  • ADT Altona Diagnostic Technologies
  • Advanced Biological Laboratories
  • Advanced Cell Diagnostics
  • Advanced Cooling Therapy
  • Advanced Genomic Solutions
  • Advanced Medical German Company of Kuwait
  • ADx Healthcare
  • Aetna
  • Affinium Pharmaceuticals
  • AFFiRiS
  • Affymetrix
  • Agena Bioscience
  • Agendia
  • Agilent Technologies
  • Air Force Research Laboratory
  • Akers Biosciences
  • Akonni Biosystems
  • Aldeyra Therapeutics
  • Alere
  • Allele Biotechnology and Pharmaceuticals
  • Any Many More Companies!

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900